Navigation Links
ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
Date:4/8/2008

d be available by the middle of this year. Once we have reviewed the data from this study, we will decide on our future development plans with microplasmin for the treatment of acute stroke."

About Stroke

Stroke is a cardiovascular disease affecting the blood vessels of the brain. Stroke is caused by a blockage of the blood vessels of the brain, depriving the brain of oxygen, and can result in severe neurological damage and death. After heart diseases and cancer, stroke is the third most frequent cause of death and the leading cause of disability in the Western world. It is estimated that over two million people suffer a stroke annually. Mortality is high with 20% of patients dying, while the majority of the remainder are left permanently disabled.

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases such as acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in late 2008, and TB-403 (Anti-PlGF), which has begun Phase I clinical trials for the treatment of cancer. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-loo
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics Announces 2007 Full Year Results
2. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
3. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
4. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
5. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
6. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
7. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
8. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
9. Compressus Completes Interoperability Implementation for E-Rad Solutions Teleradiology Customers
10. Core Informatics Completes Successful LIMS Implementation for Progenics Pharmaceuticals
11. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 RXi Pharmaceuticals Corporation (NASDAQ: ... developing innovative therapeutics, primarily in the areas of dermatology ... offering of 26 million units at a price to ... of approximately $10.4 million. Each unit consists of (i) ... purchase right to purchase 0.50 of a share of ...
(Date:5/28/2015)... , May 28, 2015  GenVec, Inc. (Nasdaq: ... Douglas J. Swirsky , will present a company ... 11 a.m. EDT on Thursday, June 4, 2015. ... Swirsky,s presentation will be available at the following link:  ... on GenVec,s website.  To access, visit www.genvec.com , ...
(Date:5/28/2015)... The Fertility Centers of New England is proud ... taken on a new and expanded role as Medical ... leadership, oversight and quality assurance for the practice. , ... team of experienced reproductive endocrinologists,” said Fertility Centers of ... “Her expertise and compassionate, individualized care have helped set ...
(Date:5/28/2015)... Whitehouse Laboratories is excited to announce ... partnership with PTI Inspection Systems. Whitehouse Labs and PTI ... custom-tailored method development and validation programs using the ... agreement includes a more formal program that facilitates cross ... This enables a more effective team approach, especially as ...
Breaking Biology Technology:RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3GenVec To Present At The Jefferies Healthcare Conference 2Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 3
... Cellumen, Inc., the Cellular,Systems Biology Company, announced today ... Center for Toxicology Research (NCTR), a,research center of ... Cellumen will use its proprietary CellCiphr(R) toxicity risk,assessment ... toxicity,compounds including both failed and marketed drugs for ...
... ... -, ... stage biotechnology company committed to the,research and product discovery against life-threatening and ... Therapeutics has been led since its,inception in 2006 by James Sapirstein, RPh, ...
... SGX Pharmaceuticals,(Nasdaq: SGXP ) today announced that ... to the U.S. Food and Drug Administration for ... molecule for the treatment of relapsed and refractory ... for CML is Gleevec(R). Although Gleevec is a,highly ...
Cached Biology Technology:Cellumen to Collaborate With the NCTR of the FDA to Apply Cellular Systems Biology (CSB(TM)) to Predictive Toxicology 2Tobira Therapeutics Inc. Announces Senior Management Team 2Tobira Therapeutics Inc. Announces Senior Management Team 3SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 2SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 3
(Date:5/21/2015)... May 21, 2015 According ... Market by Solutions (Hardware, Software, Services), by Applications (Surveillance ... others), by End-Users (Military & Defense & Commercial) ... Thermal Imaging Market is expected to grow from ... 2020, at a Compound Annual Growth Rate (CAGR) ...
(Date:5/19/2015)... YORK , May 19, 2015  Technology is ... both internally and in the cloud. Passwords and their ... use of OTP and standards-based specifications such as those ... the outmoded use of passwords presents for BYOD, COPE, ... a unified biometric identity protocol. In ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated ... human interface solutions, today announced the appointment of ... and Chief Financial Officer, reporting to Rick ... Synaptics, current Chief Financial Officer, Kathleen Bayless ... Mr. Ali brings extensive financial ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... rising from deep within the Earth are fueling the ... the rim of the 19,850-foot-high Socompa volcano in the ... team. The new study shows the emission ... vents near the summit of Socompa sustains complex microbial ...
... for example food, can be kept for a long ... University of Gothenburg, Sweden, is close to providing answers ... to carry out various biological functions. The protein,s level ... these functions is dependent on the amount of water ...
... March 3, 2009 -- Ben-Gurion University of the Negev ... technology, featuring two reversible panes that will save energy ... , "The ,Seasons Window, features the only glazing system ... or high radiant temperature near a window and reduces ...
Cached Biology News:Earth's highest known microbial systems fueled by volcanic gases 2Earth's highest known microbial systems fueled by volcanic gases 3Ben-Gurion University of the Negev researchers develop new reversible, green window technology 2
MBS 384 well satellite block unit with height adjusting heated lid, 384 well block holds 1 x 0.04 ml 384 well plate...
384 well block MBSr. Robot compatible block ejection mechanism. Stackable. (384 well block - holds 384 well plate)...
...
Buckets for 2 racks of 5 tubes, type Stago/Hitachi...
Biology Products: